Provided herein are antibodies and antigen binding fragments thereof targeting the human C-type lectin-like molecule-1 (CLL-1) protein, as well as chimeric antigen receptors (CAR) derived from such antibodies and fragments, and the uses thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cancer and tumors, and autoimmune diseases and disorders; Biological preparations for the treatment of cancer; Biologics in the nature of pharmaceutical preparations for the treatment of cancer.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cancer and tumors, and autoimmune diseases and disorders; Biological preparations for the treatment of cancer; Biologics in the nature of pharmaceutical preparations for the treatment of cancer.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services in the field of oncology and CAR T-cell therapy; arranging, organizing and conducting events, conferences and exhibitions related to oncology and CAR T-cell therapy; arranging and conducting of conferences, congresses and symposiums in the field of medicine and healthcare; educational services relating to pharmaceuticals, medical conditions, and medical treatments; providing of training relating to pharmaceuticals and the prevention, treatment and/or alleviation of medical conditions, diseases, and disorders; the provision of on-line electronic publications from a global computer network relating to pharmaceuticals and the prevention, treatment and/or alleviation of medical conditions, diseases, and disorders. Providing health and medical information and advisory services in the fields of oncology and CAR T-cell therapy; information and advisory services relating to pharmaceuticals, diseases, medical conditions, and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis, treatment, and prevention of diseases and medical disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cancer and tumors, and autoimmune diseases and disorders; Biological preparations for the treatment of cancer; Biologics in the nature of pharmaceutical preparations for the treatment of cancer
The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.
Provided herein are methods for manufacturing CAR-T cell products with high purity of TSCM subsets (>90%), independent of the variations from incoming leukapheresis. In some embodiments, to isolate the CCR7 and CD45RA double positive T cell subset, the processes described herein deplete CD45RO positive cells from leukapheresis and positively enrich for a CD4 and CD8 T cell population to isolation both TSCM and effector memory T cell (TEMRA) subsets, both of which positively express CD45RA and CCR7.
The disclosure relates to methods of prognosis and therapy, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, and CAR-based therapies).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The disclosure relates to methods of prognosis and therapy, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, and CAR-based therapies).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of neurological diseases and disorders; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of neuromuscular disorders; pharmaceutical preparations for the treatment of peripheral nervous system disorders
11.
METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE
A method and system for scheduling a patient-specific immunotherapy procedure. The method includes receiving a request on a server computing device to schedule a leukapheresis appointment for an available date and time displayed on a calendar stored in a database that is in communication with the computing device. The request can be made with a client computing device that is in communication with the server computing device via a network. Furthermore, the calendar may be updated in real time by the server computing device to show any changes to the calendar. The server computing device may automatically generate a final product date to estimate when the final product of engineered cells from the patient will be available for infusion into the patient. A manufacturing processing status for the final product of engineered cells from the patient may be updated on the calendar.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
G06Q 10/1093 - Calendar-based scheduling for persons or groups
12.
SYSTEMS, METHODS, AND KITS FOR GENERATING AND ADMINISTERING ENGINEERED T CELLS AND CD38 TARGETING COMPOUNDS AS A COMBINATION THERAPY
The present disclosure describes technologies for combination therapies using engineered T cells and a CD38 targeting compound. The technologies specifically address issues arising from combining therapeutics and generating and maximizing arising synergistic effects of the therapies while retaining and/or improving individually existing effects. The engineered T cells may include a CD38 expression modification offering protections against the CD38 targeting compound. The CD38 targeting compound may offer protection to the engineered T cells from NK cell-mediated rejection. Further, the combination therapies may target the same cells in a synergistic fashion. The technologies described herein may be embodied in methods of use, methods of manufacture, systems, engineered T cells, CD38 targeting compounds, kits, and other useful embodiments.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
13.
SYSTEMS, METHODS, AND KITS FOR GENERATING AND ADMINISTERING ENGINEERED T CELLS AND CD38 TARGETING COMPOUNDS AS A COMBINATION THERAPY
The present disclosure describes technologies for combination therapies using engineered T cells and a CD38 targeting compound. The technologies specifically address issues arising from combining therapeutics and generating and maximizing arising synergistic effects of the therapies while retaining and/or improving individually existing effects. The engineered T cells may include a CD38 expression modification offering protections against the CD38 targeting compound. The CD38 targeting compound may offer protection to the engineered T cells from NK cell-mediated rejection. Further, the combination therapies may target the same cells in a synergistic fashion. The technologies described herein may be embodied in methods of use, methods of manufacture, systems, engineered T cells, CD38 targeting compounds, kits, and other useful embodiments.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
14.
METHODS FOR GENERATING ENGINEERED LYMPHOCYTES WITH ENRICHED T MEMORY STEM CELLS
Provided herein are methods for manufacturing CAR-T cell products with high purity of TSCM subsets (>90%), independent of the variations from incoming leukapheresis. In some embodiments, to isolate the CCR7 and CD45RA double positive T cell subset, the processes described herein deplete CD45RO positive cells from leukapheresis and positively enrich for a CD4 and CD8 T cell population to isolation both TSCM and effector memory T cell (TEMRA) subsets, both of which positively express CD45RA and CCR7.
The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of characterizing the pre-infusion tumor microenvironment and determining an effective dose of a T cell immunotherapy.
Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Provided herein are chimeric transmembrane proteins, nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.
The present disclosure describes technologies for improving a T cell manufacturing process Specifically, upregulating low-density lipoprotein receptor (LDL-R) expression on a T cell surface. The described technologies are particularly suitable in manufacturing processes using of non-activated T cells in a transduction step.
The present disclosure describes technologies for improving a T cell manufacturing process. Specifically, upregulating low-density lipoprotein receptor (LDL-R) expression on a T cell surface. The described technologies are particularly suitable in manufacturing processes using of non-activated T cells in a transduction step.
The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The disclosure relates to methods for predicting a likelihood of a relapse to a cancer in a patient, methods for predicting a likelihood of a durable response to a cell therapy product in a patient in need thereof, and methods for treating a malignancy in a patient.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Immune cell engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20 and/or overexpress one or more of exogenous TCF7 and Bach2. Method of treating cancer, comprising administering the cells described herein. Method of increasing one or more of a peak fold proliferation rate, a killing efficiency, or inducing the cellular characteristics associated with naïve phenotype of an immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2. Method of generating a modified immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2.
Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The disclosure relates to methods for predicting a likelihood of a relapse to a cancer in a patient, methods for predicting a likelihood of a durable response to a cell therapy product in a patient in need thereof, and methods for treating a malignancy in a patient.
Provided herein are engineered receptors that include an extracellular domain (ECD) from a TGF-β receptor, a transmembrane domain (TMD), and that lack amino acid residues for signaling and phosphorylation, where such receptors are involved in cytokine signaling, for modulating TGF-β signaling, for methods of modulating TGF-β signaling, and for treating cancer using chimeric antigen receptors.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of cancer and tumors, and autoimmune diseases and disorders; Biological preparations for the treatment of cancer; Biologics in the nature of pharmaceutical preparations for the treatment of cancer and autoimmune diseases; Biologics in the nature of cells for medical use; Pharmaceutical preparations for gene therapy for the treatment of cancer, and tumors, and autoimmune diseases and disorders; Pharmaceutical preparations for cellular therapy for the treatment of cancer and autoimmune diseases Custom biomanufacturing of pharmaceutical preparations; Custom manufacture of biopharmaceuticals; Custom manufacture of biological tissue, blood, and cells; custom manufacturing of pharmaceutical preparations for immunotherapy; providing technical information in the field of pharmaceutical manufacturing Providing medical information; Providing medical information in the field of oncology and cell therapy
27.
DNVSIG3 AND DNVSIG8 RECEPTORS AND METHODS OF USING THE SAME
Described are dominant-negative receptor mutants of V-Set and Immunoglobulin domain containing 3 (VSIG3) receptors and V-Set and Immunoglobulin domain containing 8 (VSIG8) receptors and methods of making the same for use in applications drawn to modulating the downstream signal transduction effects of VSIG3 and VSIG8 and their corresponding ligands. The invention is drawn to use of the use of the dnVSIG3 and/or dnVSIG8 receptor mutants to mitigate immunosuppressive effects associated with functional forms of VSIG3 and/or VSIG8 in the presence of their cognate ligands.
Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the anti-PMCA antigen binding domains disclosed herein. SynNotch receptors that comprise an anti-PSCA binding domain Provided are polynucleotides encoding antibodies, fragments thereof, CARs, T cell receptors (TCR) and SynNotch receptors. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure describes storing and transporting technologies for temperature sensitive materials. More specifically, storage and transport of apheresis material. The described technologies include environmental monitoring systems, location tracking systems, an environmental control system, and customized systems and interfaces allowing for non-expert use. The storing and transporting technologies described herein may be ideally suited for the unique requirements of apheresis material.
36 - Financial, insurance and real estate services
40 - Treatment of materials; recycling, air and water treatment,
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
45 - Legal and security services; personal services for individuals.
Goods & Services
Financial administration of patient reimbursement programs;
financial administration of medication reimbursement
programs and services. Custom manufacturing of biological tissue, blood, and cells;
custom manufacturing of pharmaceutical preparations for
immunotherapy. Providing medical information in the fields of oncology,
immunology and cell therapy; providing medical information
in the fields of oncology, immunology and cell therapy via a
web site; providing medical information, consultancy and
advisory services in the fields of oncology, immunology and
cell therapy; all of the foregoing excluding any services
related to optometry, ophthalmology or other ocular care;
collection and preservation of biological tissue, blood and
cells. Providing patient advocate services in the field of the
treatment of diseases and disorders in the fields of cancer
treatments, immunotherapy and cell therapy treatments.
31.
APPARATUSES, SYSTEMS, AND METHODS FOR STORING AND TRANSPORTING A TEMPERATURE SENSITIVE MATERIAL
The present disclosure describes storing and transporting technologies for temperature sensitive materials. More specifically, storage and transport of apheresis material. The described technologies include environmental monitoring systems, location tracking systems, an environmental control system, and customized systems and interfaces allowing for non-expert use. The storing and transporting technologies described herein may be ideally suited for the unique requirements of apheresis material.
F25B 21/02 - Machines, plants or systems, using electric or magnetic effects using Peltier effectMachines, plants or systems, using electric or magnetic effects using Nernst-Ettinghausen effect
F25D 11/00 - Self-contained movable devices associated with refrigerating machinery, e.g. domestic refrigerators
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
T-Cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; pharmaceutical and
biological preparations for immunotherapy, including for
t-cell immunotherapy; pharmaceutical preparations for the
treatment of oncological and blood disorders.
42.
ALLOGENIC THERAPEUTIC CELLS WITH REDUCED RISK OF IMMUNE REJECTION
The present disclosure provides allogeneic cells that cause reduced risks of graft-versus-host disease (GVHD) and reduced risk of CD8 and NK cell rejections, for example, when used to treat diseases, such as cancer and/or autoimmune disease, in a patient. The allogeneic cells may be genetically engineered to reduce the expression or activity of CD58. Methods of preparing and using such allogeneic cells are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for t-cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
55.
ALLOGENIC THERAPEUTIC CELLS WITH REDUCED RISK OF IMMUNE REJECTION
The present disclosure provides allogeneic cells that cause reduced risks of graft-versus-host disease (GVHD) and reduced risk of CDS and NK cell rejections, for example, when used to treat diseases, such as cancer and/or autoimmune disease, in a patient. The allogeneic cells may be genetically engineered to reduce the expression or activity of CD58. Methods of preparing and using such allogeneic cells are also provided.
The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
58.
SYSTEMS AND METHODS FOR DETECTING SUSPENDED PARTICLES IN FLUIDS
The present disclosure describes an automated system for physically manipulating sample fluids, capturing images of sample fluids and detecting the presence of particles, characterizing the particles by their features (e.g., size, shape, etc.), and/or identifying particles based on those characteristics.
The disclosure relates to prognosis and impact of tumor microenvironment on efficacy of cell-based immunotherapy (e.g. T cells, TCR-based therapies, and CAR-based therapies).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
63.
SYSTEMS AND METHODS FOR DETECTING SUSPENDED PARTICLES IN FLUIDS
The present disclosure describes an automated system for physically manipulating sample fluids, capturing images of sample fluids and detecting the presence of particles, characterizing the particles by their features (e.g., size, shape, etc.), and/or identifying particles based on those characteristics.
G01N 15/0227 - Investigating particle size or size distribution by optical means using imagingInvestigating particle size or size distribution by optical means using holography
G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
G01N 15/02 - Investigating particle size or size distribution
64.
IMPACT OF TUMOR MICROENVIRONMENT ON EFFICACY OF IMMUNOTHERAPY
The disclosure relates to methods of prognosis and therapy, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, and CAR-based therapies).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of
cancer and hematological diseases and disorders; biological
preparations for use in the treatment of cancer and
hematological diseases and disorders; pharmaceutical and
biological preparations for immunotherapy, including cell
therapy.
The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
75.
CAR-T CONSTRUCTS COMPRISING A NOVEL CD19 BINDER COMBINED WITH IL18 AND METHODS OF USING THE SAME
The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL-18), compositions comprising the T cells, and methods of generating and/or using the T cells to treat diseases associated with the expression of CD19.
The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders. Providing medical and healthcare information; providing medical information in the field of pharmaceuticals and cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer and hematological diseases and disorders; biological preparations for use in the treatment of cancer and hematological diseases and disorders; pharmaceutical and biological preparations for immunotherapy, including cell therapy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in the treatment of cancer and hematological diseases and disorders; biological preparations for use in the treatment of cancer and hematological diseases and disorders; pharmaceutical and biological preparations for immunotherapy, including cell therapy.
Provided herein are methods for preparing, producing, processing, culturing, isolating, of making cells suitable for immune or cell therapy, and for their use in cell therapy. Further provided are methods for treatment of a cancer patient with such cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including for T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pharmaceutical and biological preparations for use in immunotherapy, in particular, T-Cell immunotherapy; pharmaceutical preparations for the treatment of oncological and blood disorders
99.
METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF
The United States of America, as represented by the Secretary, Department of Health and Human Serv (USA)
Inventor
Better, Marc
Feldman, Steven A.
Rosenberg, Steven A.
Abstract
Provided herein are methods for manufacturing T cells. In certain embodiments, methods for manufacturing T cells which express a cell surface receptor that recognizes a specific antigenic moiety on the surface of a target cell are provided. Also provided herein are populations of engineered T cells produced by the methods described herein and pharmaceutical compositions thereof.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
100.
ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.
